Close Menu

NEW YORK (GenomeWeb) – Having raised $200 million in financing over the last year, Somalogic is ending its fee-for-service business to focus on developing its SomaScan platform as a clinical tool.

The company is establishing collaborations with pharmaceutical companies, health systems, and other organizations that will allow it to collect and test the patient data it hopes to ultimately package for clinical use, said Stephen Williams, Somalogic's chief medical officer.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.